Table II.
Association of KIR and HLA class I ligands with survival prognosis of patients with mNSCLC by univariate analysis.
| PFS (negative vs. positive) | OS (negative vs. positive) | |||
|---|---|---|---|---|
| KIR and HLA typing (n=70) | HR (95% CI) | P-value | HR (95% CI) | P-value |
| KIR genotype | ||||
| KIR2DL5all | 0.58 (0.32–1.05) | 0.072 | 1.05 (0.54–2.05) | 0.888 |
| KIR2DL5A | 0.59 (0.32–1.10) | 0.095 | 0.96 (0.49–1.90) | 0.912 |
| KIR2DL5B | 0.64 (0.35–1.17) | 0.148 | 1.06 (0.54–2.08) | 0.870 |
| KIR2DS4del | 1.07 (0.62–1.85) | 0.797 | 0.60 (0.31–1.16) | 0.126 |
| KIR2DS4full | 1.29 (0.69–2.41) | 0.430 | 1.39 (0.66–2.91) | 0.387 |
| KIR2DS4del+/KIR2DS4full− | 0.97 (0.50–1.91) | 0.935 | 0.60 (0.26–1.37) | 0.227 |
| KIR2DS4full+/KIR2DS4del− | 1.11 (0.64–1.92) | 0.716 | 1.57 (0.81–3.06) | 0.182 |
| KIR2DS4ful+/KIR2DS4del+ | 1.20 (0.67–2.16) | 0.540 | 0.85 (0.40–1.82) | 0.673 |
| KIR3DS1 | 0.70 (0.38–1.28) | 0.243 | 0.99 (0.50–1.95) | 0.979 |
| KIR2DS1 | 0.56 (0.30–1.05) | 0.071 | 0.93 (0.47–1.85) | 0.843 |
| KIR2DS2 | 0.80 (0.38–1.69) | 0.557 | 0.89 (0.38–2.11) | 0.795 |
| KIR2DS3 | 0.58 (0.34–2.14) | 0.736 | 1.48 (0.55–3.97) | 0.436 |
| KIR2DS5 | 0.60 (0.32–1.14) | 0.118 | 1.12 (0.56–2.26) | 0.744 |
| KIR cDNA type | ||||
| KIR2DL5all | 0.70 (0.39–1.27) | 0.244 | 0.90 (0.45–1.80) | 0.760 |
| KIR2DS1 | 0.72 (0.39–1.34) | 0.300 | 1.43 (0.62–3.27) | 0.399 |
| KIR2DS4del | 1.18 (0.64–2.18) | 0.588 | 0.51 (0.26–1.01) | 0.049 |
| KIR2DS4full | 1.22 (0.67–2.24) | 0.516 | 1.55 (0.77–3.11) | 0.219 |
| KIR3DL1 | 1.40 (0.80–2.46) | 0.231 | 1.16 (0.58–2.31) | 0.669 |
| KIR3DS1 | 0.59 (0.33–1.06) | 0.075 | 0.96 (0.48–1.91) | 0.908 |
| KIR2DS4full+/KIR2DS4del− | 1.19 (0.68–2.09) | 0.540 | 1.84 (0.93–3.66) | 0.082 |
| KIR HLA ligand | ||||
| HLA-C2 | 1.21 (0.67–2.18) | 0.523 | 1.23 (0.59–2.57) | 0.574 |
| HLA-Bw4T80 | 0.69 (0.39–1.22) | 0.199 | 0.54 (0.28–1.05) | 0.066 |
| HLA-Bw4I80 | 0.70 (0.39–1.25) | 0.225 | 0.93 (0.43–1.99) | 0.851 |
| HLA-ABw4 | 1.31 (0.73–2.35) | 0.364 | 1.72 (0.81–3.67) | 0.156 |
| HLA-C genotype | ||||
| C1C1 | 1.31 (0.69–2.47) | 0.614 | 1.33 (0.60–2.95) | 0.746 |
| C1C2 | 0.78 (0.24–2.57) | 0.86 (0.20–3.62) | ||
| C2C2 | 0.60 (0.17–2.12) | 0.64 (0.14–3.04) | ||
Bold print, P-values <0.1. mNSCLC, metastatic non-smallcell lung cancer; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; KIR, killer-cell immunoglobulin-like receptor; HLA, human leukocyte antigen. Frequencies of >20% and <80% for KIRs or HLA ligands were included in the survival analysis.